Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px
Collaboration › Details

Bayer–Berkeley Lights: plant research, 202108 collab multi-year €na RnD seeds and traits using Berkeley Lights Platform


Period Period 2021-08-11
  Predecessor Bayer–Berkeley Lights: cell line development, 201709– collab using Beacon platform for cell line development + antibody discovery
Organisations Partner, 1st Bayer CropScience (Group)
  Group Bayer (Group)
  Partner, 2nd Berkeley Lights Inc. (Nasdaq: BLI)
Products Product plant breeding technology
  Product 2 Berkeley Lights Platform
Person Person White, Brianna (Bayer 202108 Head of Trait Design + Science at Bayer Cropscience)

Berkeley Lights, Inc.. (8/11/21). "Press Release: Berkeley Lights and Bayer Announce a Multi-year Agreement Aimed at Revolutionizing the Discovery of Next-generation Traits". Emeryville, CA.

Agreement debuts Berkeley Lights’ rapid high-throughput functional screening capability to accelerate and expand the discovery and development of Bayer Crop Science’s seeds and traits product pipeline

Berkeley Lights, Inc. (Nasdaq: BLI) a leader in the functional characterization of live biology, announced a multi-year agreement with Bayer to develop and perform high-throughput functional screening workflows aimed at accelerating and expanding the discovery of novel traits. Terms of the agreement were not disclosed.

Berkeley Lights will leverage its platform to screen individual variants of bioactives for Bayer in a massively high-throughput manner. The outcome will be a significant acceleration of the agricultural leader’s pipeline for discovery and development of novel traits. This agreement marks the first application of Berkeley Lights’ technology for use in the agricultural sector.

“After evaluating the technology landscape, it became clear that the Berkeley Lights Platform is uniquely positioned to enable Bayer Crop Science to deliver on our commitment for world-class innovation and standards in sustainability for farmers, consumers and the environment,” said Brianna White, Head of Trait Design and Science for Bayer. “Our agreement with Berkeley Lights to develop and perform high-throughput functional screening workflows will enable us to accelerate and expand our trait discovery program.”

“We are excited to support Bayer in the discovery and development of novel traits,” said Eric Hobbs, PhD, chief executive officer of Berkeley Lights. “This agreement is an example of Berkeley Lights executing on our commitment to deploy our technologies into new, large market segments. Our proprietary approach to high-throughput functional screening is applicable to a variety of sectors and applications even beyond agriculture, including antibody, therapeutic protein, and enzyme engineering for pharmaceutical, life science, and industrial products.”

About Berkeley Lights

Berkeley Lights is a leading digital cell biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional, and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect™ chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain.

The Berkeley Lights Platform is FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Berkeley Lights or its products, they are forward-looking statements reflecting the current beliefs and expectations of management. Such forward-looking statements involve substantial known and unknown risks and uncertainties that relate to future events, and actual results and product performance could differ significantly from those expressed or implied by the forward-looking statements. Berkeley Lights undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties relating to the Company’s growth and evolution, including its ability to accelerate, expand and/or revolutionize the discovery of novel traits and to expand its technology approach to high-throughput functional screening into new sectors and applications, see the statements in the "Risk Factors" sections, and elsewhere, in our filings with the U.S. Securities and Exchange Commission.

Berkeley Lights Press Contact

Investor Contact

Record changed: 2022-01-02


Picture [iito] No Content Marketing 650x100px

More documents for Bayer (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group BioTech Showcase 2022 For Investors 650x300

» top